Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Dapsone Gel, 7.5%, (USRLD: Aczone® Gel 7.5%). Dapsone Gel is used to treat acne and will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,053 INR | -0.52% | -3.25% | +52.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.78% | 12.81B | |
+16.31% | 42.32B | |
+16.11% | 21.29B | |
+19.33% | 15.29B | |
+18.71% | 14.36B | |
-0.05% | 6.79B | |
-12.40% | 6.58B | |
-8.87% | 5.73B | |
+14.28% | 5.51B | |
+7.31% | 4.91B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
- News Zydus Lifesciences Limited
- Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%